Keyword: Circassia



When it went public in 2014, Circassia was to be the herald of a renaissance for U.K. biotech IPOs. Instead, its pipeline of allergy treatments failed one by one, leading the Oxford-based company to ax all of them and eventually delist from the London Stock Exchange.

FierceBiotech’s Rotten Tomatoes

Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.